Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany

BACKGROUND: Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient populations underrepresented in clinical trials, e.g. immunocompromised patients. Additionally,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lancet Reg Health Eur
Hauptverfasser: Jensen, Bjoern, Luebke, Nadine, Feldt, Torsten, Keitel, Verena, Brandenburger, Timo, Kindgen-Milles, Detlef, Lutterbeck, Matthias, Freise, Noemi F, Schoeler, David, Haas, Rainer, Dilthey, Alexander, Adams, Ortwin, Walker, Andreas, Timm, Joerg, Luedde, Tom
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2021
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8278033/
https://ncbi.nlm.nih.gov/pubmed/34278371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lanepe.2021.100164
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge